ArticleVeterinary dermatology2026
An Open-Label Split-Body Clinical Trial Evaluating Therapeutic Efficacy and Safety of Cold Atmospheric Plasma in Canine Acute Otitis Externa.
Article in Veterinary dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCold atmospheric plasma (CAP) offers a novel, nonpharmacological approach with potent antimicrobial, anti-inflammatory and wound-healing properties without harming healthy tissue. In vitro studies have demonstrated its antimicrobial efficacy against key pathogens implicated in canine otitis externa (OE), a condition prone to chronicity if poorly managed.
objectivesThis study evaluated CAP's therapeutic efficacy and safety in treating canine acute OE. ANIMALS: Twenty-two dogs with bilateral acute OE. MATERIALS AND
methodsDogs were divided into two equal groups with different bilateral treatment protocols. In Group 1, one ear was treated twice daily with topical antibiotic/antifungal/corticosteroid for 10 days (STD
resultsSignificant reductions in OTIS-3 and cytological score were observed over time in both CAP groups, similar to STD groups (p < 0.01). Treatment response in CAP groups was rated good-to-excellent by nearly all investigators and owners. CAP demonstrated high tolerability, with no adverse effects. CONCLUSIONS AND CLINICAL RELEVANCE: CAP may represent a promising adjunctive therapy in the management of acute OE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.